ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HCM HUTCHMED China Limited

16.75
-0.10 (-0.59%)
Last Updated: 03:37:43
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
HUTCHMED China Limited HCM NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
-0.10 -0.59% 16.75 03:37:43
Open Price Low Price High Price Close Price Previous Close
16.93 16.69 17.05 16.85
more quote information »

Recent News

Date Time Source Heading
28/3/202411:00GLOBEHUTCHMED Announces Savolitinib sNDA Accepted in China for..
22/3/202411:00GLOBEHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase..
05/3/202422:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202422:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202422:40EDGAR2Form 20-F - Annual and transition report of foreign private..
28/2/202422:30GLOBEHUTCHMED Reports 2023 Full Year Results and Provides..
07/2/202422:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202411:00GLOBEHUTCHMED Highlights Presentation of Phase III Data on..
02/2/202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/2/202419:30GLOBEHUTCHMED Announces that Inmagene Exercises Option to License..
01/2/202422:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202419:30GLOBEHUTCHMED to Announce 2023 Final Results
30/1/202422:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202415:53GLOBEHUTCHMED Receives ELUNATEĀ® (fruquintinib) Marketing Approval..
11/1/202422:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/1/202418:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
11/1/202411:00GLOBEHUTCHMED Announces NDA Acceptance in China for Sovleplenib..
29/12/202322:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202322:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202322:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202318:00RNSNONHutchmed (China) Limited Completed Enrollment of Phase..
13/12/202315:30GLOBEHUTCHMED Announces Continued Inclusion of ELUNATEĀ®..
13/12/202311:00GLOBEHUTCHMED Announces that it has Completed Enrollment of a..
07/12/202322:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202322:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202318:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
01/12/202311:00GLOBEHUTCHMED Highlights Clinical Data to be Presented at 2023..
30/11/202322:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/11/202300:35GLOBEDeutsche Bank ADR Investor Conference: Presentations Now..
09/11/202322:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/11/202311:11GLOBEHUTCHMED Announces that Takeda Receives U.S. FDA Approval of..
01/11/202323:35GLOBEInternational companies to host live webcasts at Deutsche..
24/10/202321:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202321:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202319:30RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
29/9/202320:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/9/202318:30GLOBEHUTCHMED Announces Submission of New Drug Application for..
14/9/202320:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202320:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202318:30GLOBEHUTCHMED Highlights Presentation of Results from the Phase..
12/9/202316:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
12/9/202310:00GLOBEHUTCHMED Completes Patient Enrollment of a Bridging Study of..
31/8/202320:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202320:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202316:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
29/8/202310:00GLOBEHUTCHMED Receives Breakthrough Therapy Designation in China..
21/8/202320:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/8/202310:00GLOBEHUTCHMED Announces that the Sovleplenib Phase III ESLIM-01..
07/8/202320:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/7/202321:41GLOBEHUTCHMED Reports 2023 Interim Results and Provides..

Your Recent History

Delayed Upgrade Clock